OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC jointly filed a statement of changes in beneficial ownership with the SEC on November 4, 2026, reporting transactions in Aspen Neuroscience, Inc. common stock dated November 2, 2026, in connection with the company's initial public offering.
Key Highlights
- Preferred stock conversion: Five series of convertible preferred stock (Series Seed-2, A-1, A-2, B, and C) automatically converted into common stock on a 1-for-9.8821 basis upon completion of Aspen Neuroscience's IPO, for no additional consideration.
- Shares converted: The five conversion transactions produced 196,541, 642,745, 616,984, 625,743, and 507,119 shares of common stock, respectively, all on November 2, 2026.
- Open-market purchase: OrbiMed also acquired 1,000,000 shares of common stock in the IPO at a price of $15 per share.
- Resulting ownership: Following all reported transactions, the reporting persons beneficially own 3,589,132 shares of common stock indirectly through OrbiMed Private Investments VII, LP.
- Dual reporting persons: The filing was jointly submitted by OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, both listed as director and 10% owner of Aspen Neuroscience.
- Board representation: According to the filing, the reporting persons designated Peter Thompson, a member of OrbiMed Advisors, to serve on Aspen Neuroscience's board of directors.
OrbiMed's Transactions at the Aspen Neuroscience IPO
OrbiMed Advisors LLC and its affiliate OrbiMed Capital GP VII LLC reported a series of transactions on November 2, 2026, all tied to the completion of the initial public offering of Aspen Neuroscience, Inc. (NASDAQ:ASPE), a clinical-stage neuroscience company. According to the filing, all securities are held indirectly through OrbiMed Private Investments VII, LP, a fund for which OrbiMed Capital GP VII LLC serves as general partner and OrbiMed Advisors LLC serves as managing member.
The filing states that, pursuant to Aspen Neuroscience's Amended and Restated Certificate of Incorporation, each share of Series Seed-2, Series A-1, Series A-2, Series B, and Series C Convertible Preferred Stock automatically converted into common stock upon the IPO's completion. The conversion ratio was 1-for-9.8821, with no additional consideration required. The five conversion transactions produced a combined 2,589,132 shares of common stock. Separately, the reporting persons purchased 1,000,000 shares of common stock directly in the IPO at a stated price of $15 per share, bringing the total beneficially owned position to 3,589,132 shares following all reported transactions.
OrbiMed Advisors exercises investment and voting power over the shares through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, according to the filing. Each of those individuals, as well as the reporting entities, disclaimed beneficial ownership of the reported securities except to the extent of any pecuniary interest. The filing was signed by Carl L. Gordon on behalf of both OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC on November 4, 2026.
What Was Disclosed
OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC reported the automatic conversion of five series of preferred stock and a purchase of 1,000,000 common shares at $15 each in connection with the Aspen Neuroscience IPO, resulting in indirect beneficial ownership of 3,589,132 shares of common stock.




Please wait processing your request...